Home›Tetrabenazine›Tetrabenazine + Carbidopa And Levodopa

Does Tetrabenazine Interact with Carbidopa And Levodopa?

CDI records a contraindicated classification for Tetrabenazine and Carbidopa And Levodopa. The stored summary is: Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic benefit. The mechanism involves dopamine depletion. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Contraindicated
Tetrabenazine Class
Vesicular Monoamine Transporter 2 Inhibitor
Carbidopa And Levodopa Class
Aromatic Amino Acid Decarboxylation Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Dopamine depletion

What To Tell Your Doctor or Pharmacist

If you are taking Tetrabenazine and your doctor is considering prescribing Carbidopa And Levodopa (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Tetrabenazine(Xenazine)+💊 Carbidopa And Levodopa(Rytary)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
CDI classifies this record as contraindicated. Confirm the applicable product labeling with your prescriber or pharmacist.
Severity scale
MinorContra
On record
Yes
Drug A class
Vesicular Monoamine Transporter 2 Inhibitor
Drug B class
Aromatic Amino Acid Decarboxylation Inhibitor
Source
NLP:carbidopa and levodopa

What this means in plain English

Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic benefit.

About Tetrabenazine and Carbidopa And Levodopa

Tetrabenazine is a Vesicular Monoamine Transporter 2 Inhibitor, while Carbidopa And Levodopa is an Aromatic Amino Acid Decarboxylation Inhibitor. You may recognize them by the brand names Xenazine and Rytary. Tetrabenazine additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:carbidopa and levodopa

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Tetrabenazine and Carbidopa And Levodopa against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations